Clinical trials: Schizophrenia Spectrum Disorder
Schizophrenia, Hallucinations
Evaluation of Internet-based Cognitive Behavioral Self-help Treatments for People With Psychosis
Schizophrenia is a severe mental disorder which is accompanied by an enormous individual and societal burden. Despite established efficacy of cognitive behavioral therapy for psychosis (CBTp), its dissemination into routine…
- Conditions
- Schizophrenia, Hallucinations, Persecutory Delusion
- Trial name
- EviBaS (NCT02974400)
- Testing
- Internet-based, CBT-oriented, guided self-help
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 101 people
- Sponsor
- University of Bern
Schizophrenia
A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia
A Clinical Study to learn if SEP-363856 has physical dependence in adults with schizophrenia. This study will be held in approximately 6 study sites in the United States.
- Trial name
- NCT05848700
- Testing
- SEP-363856
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Varenicline (Chantix) is a smoking cessation treatment that was approved in 2006 by the FDA for treatment of nicotine dependence and may be particularly beneficial in smokers with schizophrenia or bipolar disorder.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Smoking
- Trial name
- SCRP (NCT00621777)
- Testing
- Varenicline
- Where
- 10 sites in United States
- Volunteers
- 247 people
- Sponsor
- Massachusetts General Hospital
Bipolar I Disorder, Schizoaffective Disorder
Open Label Extension Study of NCT06221852
This is a 12-week open-label extension study for participants completing study NCT06221852.
- Conditions
- Bipolar I Disorder, Schizoaffective Disorder, Psychosis
- Trial name
- NCT06558201
- Testing
- Ketogenic diet
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mclean Hospital
Schizophrenia
Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)
Participants who have completed the 6-week trial P05688 can be screened for eligibility for this 26-week extension study in which they will continue treatment.
- Trial name
- NCT01617200
- Testing
- Asenapine, Olanzapine
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Forest Laboratories
Schizophrenia
Effects of Narrative Enhancement and Cognitive Therapy (NECT) on Self-stigma in Patients With Schizophrenia
This study aims to explore the effect of narrative enhancement and cognitive therapy in improving self-stigma, self-esteem, depression and hope of patients with chronic schizophrenia.
- Trial name
- NCT03967431
- Testing
- Narrative Enhancement and Cognitive Therapy (NECT)
- Where
- Taiwan
- Volunteers
- 86 people
- Sponsor
- National Yang Ming Chiao Tung University
Major Depressive Disorder, Bipolar Disorder
Taking Action for College Students
The goal of this research is to investigate whether a peer-delivered illness self-management program called Taking Action can help college students with serious mental illnesses.
- Conditions
- Major Depressive Disorder, Bipolar Disorder, Schizophrenia
- Trial name
- NCT06700902
- Testing
- Taking Action
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Temple University
Schizophrenia, Schizophrenic Disorders
Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.
The purpose of this open-label study is to evaluate the long-term (6-month) safety and tolerability of extended-release paliperidone, an atypical antipsychotic, given in flexible dosages to adolescents with schizophrenia.
- Conditions
- Schizophrenia, Schizophrenic Disorders, Psychotic Disorders, Dementia Praecox
- Trial name
- NCT00488319
- Testing
- Paliperidone ER
- Where
- 53 sites in United States, Belgium and 9 more
- Volunteers
- 400 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia, Schizoaffective Disorder
Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS)
This study will test whether repetitive transcranial magnetic stimulation (rTMS) is helpful in treating negative symptoms and social deficits of schizophrenia.
- Trial name
- NCT00517075
- Testing
- Transcranial Magnetic Stimulation (TMS), repetitive transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- New York State Psychiatric Institute
Severe Mental Illness, Nicotine Dependence
Electronic Decision Support Systems for Smokers With Severe Mental Illness
This randomized clinical trial among SMI smokers assessed whether the EDSS with carbon monoxide monitor and health-checklist feedback lead to higher rates of initiation of smoking cessation treatment, days of smoking abstinence…
- Conditions
- Severe Mental Illness, Nicotine Dependence, Schizophrenia, Tobacco Use Disorder
- Trial name
- NCT01412866
- Testing
- EDSS with CO feedback and health checklist, EDSS with health checklist feedback alon
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia, Cognitive Dysfunction
Supportive Psychotherapy as Adjunct to Risperidone for Cognitive Function and Inflammation in Schizophrenia
This study examined whether adding structured supportive psychotherapy to risperidone treatment is more effective than risperidone alone in improving cognitive function and reducing inflammation in patients with schizophrenia.
- Conditions
- Schizophrenia, Cognitive Dysfunction, Inflamation
- Trial name
- SUPPORT-SCZ (NCT07477301)
- Testing
- Structured Supportive Psychotherapy, Risperidone 2 mg
- Where
- Indonesia
- Volunteers
- 46 people
- Sponsor
- Hasanuddin University
Schizophrenia
Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) Antagonism
This study investigates the common features of electrophysiological measures in schizophrenia and effects of NMDA antagonist ketamine in healthy volunteers.
- Trial name
- NCT02675530
- Testing
- ketamine
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Yale University
Ketamine Abuse, Psychotic Disorders
Substance Misuse To Psychosis for Ketamine (SToP-K)
Evidence suggests that repeated or chronic ketamine use, as compared to acute ketamine users, posed a higher clinical risk of developing psychotic disorders, potentially related to the underlying chronic N-methyl-D-aspartate…
- Conditions
- Ketamine Abuse, Psychotic Disorders, Substance Use Disorders, Schizophrenia
- Trial name
- NCT03485339
- Testing
- genome testing
- Where
- 2 sites in Hong Kong
- Volunteers
- 162 people
- Sponsor
- The University of Hong Kong
Clozapine Resistant Schizophrenia
Maintenance Electroconvulsive Therapy (ECT) Versus Aripiprazole in Clozapine-resistant Schizophrenia
The pharmacological treatment options in schizophrenia developing resistance to clozapine are limited. Few studies have found ECT as beneficial in TRS, including CRS.
- Trial name
- NCT06501339
- Testing
- maintenance ECT, Aripiprazole tablet
- Volunteers
- 40 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Schizophrenia, Negative Symptoms of Schizophrenia
Berberine in Treating Negative Symptoms of Schizophrenia: Clinical Efficacy and Mechanisms
"Negative" symptoms are a major challenge for people with schizophrenia (SZ) and are a key reason why they struggle with everyday functioning.
- Trial name
- NCT07356765
- Testing
- Berberine
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tianjin Anding Hospital
Parasite and Infestation Physician-Patient Diagnostic Incongruency
The Parasite and Infestation Study
Many people have evidence of bugs, parasites, and infestation, but are told by others that they cannot find a cause. This distressing and frustrating experience can last for years, as the person seeks answers.
- Trial name
- NCT07849907
- Testing
- No intervention - observational study
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Vanderbilt University Medical Center
Schizophrenia, Schizoaffective Disorder
Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia
This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.
- Trial name
- NCT00588731
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Yale University
Schizophrenia, Schizoaffective Disorder
Schizophrenia Treatment Adherence Investigation (STAI)
The primary objective of this treatment review and feedback program is to quantify the risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia.
- Trial name
- NCT01001481
- Testing
- Risk status for medication adherence
- Volunteers
- 550 people
- Sponsor
- Janssen-Cilag Pty Ltd
Schizoaffective Disorder, Schizophrenia
Effectiveness of a Mobile Texting Intervention for People With Serious Mental Illness
Testing an mHealth mobile interventionist texting program on illness management.
- Conditions
- Schizoaffective Disorder, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT03062267
- Testing
- Mobile Interventionist
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of Washington
Schizophrenia, Bipolar Disorder
Impact of Genetic Counseling for Individuals With Mental Illness
People who have experienced mental illnesses like schizophrenia, bipolar disorder or schizoaffective disorder often have a poor understanding of the causes of their illness, and that they are often very worried about how the…
- Conditions
- Schizophrenia, Bipolar Disorder, Schizoaffective Disorder
- Trial name
- NCT00713804
- Testing
- Genetic Counseling, Educational Booklet
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- University of British Columbia